Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd., commonly referred to as Taro, is a prominent player in the global pharmaceutical industry, headquartered in Israel. Founded in 1950, Taro has established a strong presence in North America, Europe, and Asia, focusing on the development, manufacturing, and marketing of generic and specialty pharmaceuticals. The company is renowned for its extensive portfolio of high-quality products, including topical treatments, dermatological solutions, and oral medications. Taro's commitment to innovation and quality has positioned it as a trusted provider in the healthcare sector. With a robust pipeline and a reputation for excellence, Taro continues to achieve significant milestones, solidifying its market position and contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Taro Pharmaceutical Industries Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taro Pharmaceutical Industries Ltd.'s score of 67 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Taro Pharmaceutical Industries Ltd., headquartered in Israel (IL), currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Sun Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. As of now, Taro has not established any documented reduction targets or specific climate pledges. The absence of emissions data suggests that Taro may be in the early stages of developing its sustainability strategy or reporting framework. Given its relationship with Sun Pharmaceutical Industries Limited, any climate initiatives or emissions data may be inherited from this parent company. However, specific details regarding emissions performance or reduction targets from Sun Pharmaceutical Industries Limited have not been disclosed in the available information. In summary, Taro Pharmaceutical Industries Ltd. is currently lacking in specific emissions data and reduction commitments, with potential influences from its parent company, Sun Pharmaceutical Industries Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Taro Pharmaceutical Industries Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
